Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05726292 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study sites: 2 to 4v7
  2. Re-verified, no change to tracked fieldsv6
  3. Primary completion date: Oct 1, 2025 to Oct 1, 2027
    • Start date: Oct 9, 2023 to Jan 6, 2025
    • Study completion date: Apr 1, 2029 to Apr 1, 2028
    v5
  4. Study sites: 1 to 2v4
  5. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Apr 1, 2025 to Oct 9, 2023
    v3
  6. Start date: Apr 1, 2023 to Apr 1, 2025v2
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Researchers conducting this study hope to learn about the safety and effectiveness of combining two study drugs, relacorilant and enzalutamide, plus androgen deprivation therapy (ADT), also known as hormone therapy. This study is for individuals who have been diagnosed with advanced, high-risk prostate cancer and standard therapies available to treat your disease have not been effective. Participation in this research will last about 3 years and 9 months.
Trial Details
NCT Number NCT05726292
Lead Sponsor University of Chicago
Conditions
(from sponsor)		 Prostate Cancer, Prostate Adenocarcinoma
Related terms Prostatic Neoplasms
Enrollment 90 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov